Niepublicznego Zakladu Opieki Zdrowotnej Specjalistyczny Osrodek Internistyczno Diabetologiczny

The centre in Bialystok conducts studies aimed at improving glycaemic control in adults with type 2 diabetes, exploring both injectable and oral therapies.

• Weekly basal insulin switched from daily regimens
• Oral agents targeting blood sugar reduction
• Combination of insulin with non‑insulin drugs
• Safety and tolerability assessments

These trials reflect the site’s focus on advancing diabetes care while supporting patients in everyday management.

Research at the facility includes investigations into effective strategies for individuals who are overweight or obese without diabetes, seeking sustainable weight loss.

• Novel agents influencing body weight
• Long‑term percentage change in body weight
• Impact on metabolic health markers
• Patient‑reported outcomes on quality of life

The work supports the centre’s commitment to tackling metabolic disease through innovative therapies.

Studies are evaluating how new treatments can slow the progression of chronic kidney disease in people with type 2 diabetes who are also overweight.

• Surrogate markers of renal decline
• Comparison of combination therapy versus monocomponents
• Role of weight reduction on kidney outcomes
• Integration of metabolic and renal health assessments

The Niepublicznego Zakladu Opieki Zdrowotnej Specjalistyczny Osrodek Internistyczno Diabetologiczny leverages its expertise to address this high‑risk population.